JP2022531205A5 - - Google Patents

Info

Publication number
JP2022531205A5
JP2022531205A5 JP2021564373A JP2021564373A JP2022531205A5 JP 2022531205 A5 JP2022531205 A5 JP 2022531205A5 JP 2021564373 A JP2021564373 A JP 2021564373A JP 2021564373 A JP2021564373 A JP 2021564373A JP 2022531205 A5 JP2022531205 A5 JP 2022531205A5
Authority
JP
Japan
Prior art keywords
rsv
pharmaceutical composition
monoclonal antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030619 external-priority patent/WO2020223435A1/en
Publication of JP2022531205A publication Critical patent/JP2022531205A/ja
Publication of JP2022531205A5 publication Critical patent/JP2022531205A5/ja
Priority to JP2025014950A priority Critical patent/JP2025072444A/ja
Pending legal-status Critical Current

Links

JP2021564373A 2019-04-30 2020-04-30 抗rsv抗体の投与レジメン及び抗rsv抗体を含む組成物 Pending JP2022531205A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014950A JP2025072444A (ja) 2019-04-30 2025-01-31 抗rsv抗体の投与レジメン及び抗rsv抗体を含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014950A Division JP2025072444A (ja) 2019-04-30 2025-01-31 抗rsv抗体の投与レジメン及び抗rsv抗体を含む組成物

Publications (2)

Publication Number Publication Date
JP2022531205A JP2022531205A (ja) 2022-07-06
JP2022531205A5 true JP2022531205A5 (cg-RX-API-DMAC7.html) 2023-05-11

Family

ID=70779897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564373A Pending JP2022531205A (ja) 2019-04-30 2020-04-30 抗rsv抗体の投与レジメン及び抗rsv抗体を含む組成物
JP2025014950A Pending JP2025072444A (ja) 2019-04-30 2025-01-31 抗rsv抗体の投与レジメン及び抗rsv抗体を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014950A Pending JP2025072444A (ja) 2019-04-30 2025-01-31 抗rsv抗体の投与レジメン及び抗rsv抗体を含む組成物

Country Status (15)

Country Link
US (3) US12024553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962940A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022531205A (cg-RX-API-DMAC7.html)
KR (1) KR20220002427A (cg-RX-API-DMAC7.html)
CN (1) CN113825767A (cg-RX-API-DMAC7.html)
AU (1) AU2020265676A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014370A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192776A1 (cg-RX-API-DMAC7.html)
IL (1) IL287443A (cg-RX-API-DMAC7.html)
MX (1) MX2021013248A (cg-RX-API-DMAC7.html)
SG (1) SG11202111748TA (cg-RX-API-DMAC7.html)
TW (1) TWI861099B (cg-RX-API-DMAC7.html)
WO (1) WO2020223435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20240055097A (ko) * 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Similar Documents

Publication Publication Date Title
JP2023517236A5 (cg-RX-API-DMAC7.html)
TWI859164B (zh) 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法
US20200040073A1 (en) Methods for administering anti-il-5 antibodies
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
JP2021501214A5 (cg-RX-API-DMAC7.html)
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023528441A5 (cg-RX-API-DMAC7.html)
JP7722991B2 (ja) 抗fcrn抗体を用いた温熱自己免疫性溶血性貧血の治療方法
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
JP2003531866A (ja) 抗体を用いた呼吸器疾患の組合せ治療法
SG11202111748TA (en) Dosage regimens for and compositions including anti-rsv antibodies
JP2022514561A5 (cg-RX-API-DMAC7.html)
JP2025500483A5 (cg-RX-API-DMAC7.html)
JP2023535792A (ja) コロナウイルス治療のための抗cd3抗体
JP2024177399A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
CN121015902A (zh) 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
JP2023523096A5 (cg-RX-API-DMAC7.html)
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
EP4673433A2 (en) Methods for treating influenza infections
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies
WO2025242619A1 (en) Treatment for mucus plugging
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
WO2024146630A1 (zh) 一种tslp抗体治疗哮喘的方法
TW202340237A (zh) 尼塞韋單抗預防呼吸道融合細胞病毒下呼吸道感染
TW202547886A (zh) 用於治療c1s介導的疾病和病症的組成物、劑量和方法